US · FEED
ENvue Medical, Inc.
- Sector
- Healthcare · Medical - Specialties
- Headquarters
- Tyler 80333
- Website
- nanovibronix.com
Price · as of 2024-12-31
$1.19
Market cap 2.26M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $13,175.22 | +1,107,061.34% |
| Intrinsic Value(DCF) | $233,005.17 | +19,580,166.39% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $10,780.00 | $31,598.17 | $0.00 | $0.00 | $58,591.30 |
| 2016 | $13,640.00 | $5,902.27 | $271.36 | $0.00 | $0.00 |
| 2017 | $10,120.00 | $36,140.57 | $2,257.37 | $0.00 | $0.00 |
| 2018 | $9,020.00 | $13,794.67 | $4.15 | $0.00 | $0.00 |
| 2019 | $6,006.00 | $6,284.65 | $2,567.40 | $0.00 | $0.00 |
| 2020 | $2,486.00 | $30,488.68 | $158,585.83 | $0.00 | $0.00 |
| 2021 | $1,674.20 | $8,710.90 | $17,497,630.90 | $0.00 | $0.00 |
| 2022 | $387.20 | $2,858.69 | $971.76 | $0.00 | $19,017.84 |
| 2023 | $100.21 | $37,051.62 | $5,748,774.06 | $0.00 | $0.00 |
| 2024 | $39.38 | $13,175.22 | $69,830.02 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates ENvue Medical, Inc.'s (FEED) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $13,175.22
- Current price
- $1.19
- AI upside
- +1,107,061.34%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$233,005.17
+19,580,166.39% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| FEED | ENvue Medical, Inc. | $1.19 | 2.26M | +1,107,061% | +19,580,166% | — | — | -0.29 | 1.69 | 0.42 | -0.12 | — | 1.69 | 58.95% | -140.03% | -144.84% | -160.56% | -1021.97% | -71.92% | 0.19 | -26.53 | 1.22 | 0.37 | 0.17 | -4114.00% | 1205.00% | -3009.00% | -237.05% | -0.92 | -718.69% | 0.00% | 0.00% | 0.00% | -0.12 | -0.17 | 0.17 | -29.07 |
About ENvue Medical, Inc.
NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Tyler, TX.
- CEO
- Doron Robert Besser
- Employees
- 31
- Beta
- 2.21
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($233,005.17 ÷ $1.19) − 1 = +19,580,166.39% (DCF, example).